Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NATO official says members often aren't buying weapons together, and it's a mistake - 2South African radio presenter among five charged over Russia recruitment plot
- 3Vote in favor of Your Number one kind of pie
- 4Video Conferencing Instruments for Virtual Gatherings
- 5Invigorating Spots To Go Kayaking All over The Planet
- A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- Top Fascinating Organic products: Which One Might You Want to Attempt?
- EU Council president: Ukraine should receive binding guarantees
- How effective is the flu shot this year? New report shows promising results
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- New Cheetos and Doritos will be free of artificial dyes
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- One-third of asylum applications by Iranians approved in Germany
